NASDAQ:BDSIBioDelivery Sciences International Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BioDelivery Sciences International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.14 +0.60 (+13.22 %) (As of 08/14/2020 04:00 PM ET) Add Compare Share Today's Range$4.58Now: $5.14▼$5.4550-Day Range$4.07MA: $4.33▼$4.6952-Week Range$2.85Now: $5.14▼$7.21Volume8.10 million shsAverage Volume1.07 million shsMarket Capitalization$518.80 millionP/E Ratio102.80Dividend YieldN/ABeta0.72 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in opioid tolerant adult patients with cancer. The company also develops buprenorphine extended release injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingBioDelivery Sciences International has received a consensus rating of Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.46, BioDelivery Sciences International has a potential upside of 64.7% from its current price of $5.14.Amount of Analyst CoverageBioDelivery Sciences International has only been the subject of 4 research reports in the past 90 days. Previous Next 3.1 Community Rank Outperform VotesBioDelivery Sciences International has received 537 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBioDelivery Sciences International has received 342 “underperform” votes. (Add your “underperform” vote.)Community SentimentBioDelivery Sciences International has received 61.09% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about BioDelivery Sciences International and other stocks. Vote “Outperform” if you believe BDSI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BDSI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBioDelivery Sciences International does not currently pay a dividend.Dividend GrowthBioDelivery Sciences International does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioDelivery Sciences International insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $99,664.00 in company stock.Percentage Held by InsidersOnly 8.57% of the stock of BioDelivery Sciences International is held by insiders.Percentage Held by Institutions69.16% of the stock of BioDelivery Sciences International is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for BioDelivery Sciences International are expected to grow by 138.89% in the coming year, from $0.18 to $0.43 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioDelivery Sciences International is 102.80, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 17.46.Price to Earnings Ratio vs. SectorThe P/E ratio of BioDelivery Sciences International is 102.80, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.21.Price to Book Value per Share RatioBioDelivery Sciences International has a P/B Ratio of 6.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.88 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:BDSI Previous Symbol CUSIP09060J10 CIK1103021 Webwww.bdsi.com Phone919-582-9050Debt Debt-to-Equity Ratio0.92 Current Ratio2.81 Quick Ratio2.49Price-To-Earnings Trailing P/E Ratio102.80 Forward P/E Ratio28.56 P/E GrowthN/A Sales & Book Value Annual Sales$111.39 million Price / Sales4.66 Cash Flow$0.21 per share Price / Cash Flow24.80 Book Value$0.84 per share Price / Book6.12Profitability EPS (Most Recent Fiscal Year)$0.10 Net Income$-15,310,000.00 Net Margins4.23% Return on Equity17.84% Return on Assets6.90%Miscellaneous Employees178 Outstanding Shares100,934,000Market Cap$518.80 million Next Earnings Date11/10/2020 (Estimated) OptionableOptionable $5.14 +0.60 (+13.22 %) (As of 08/14/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive BDSI News and Ratings via Email Sign-up to receive the latest news and ratings for BDSI and its competitors with MarketBeat's FREE daily newsletter. BioDelivery Sciences International (NASDAQ:BDSI) Frequently Asked Questions How has BioDelivery Sciences International's stock price been impacted by COVID-19? BioDelivery Sciences International's stock was trading at $3.96 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BDSI stock has increased by 29.8% and is now trading at $5.14. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of BioDelivery Sciences International? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioDelivery Sciences International in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BioDelivery Sciences International. When is BioDelivery Sciences International's next earnings date? BioDelivery Sciences International is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for BioDelivery Sciences International. How were BioDelivery Sciences International's earnings last quarter? BioDelivery Sciences International, Inc. (NASDAQ:BDSI) posted its quarterly earnings results on Wednesday, August, 5th. The specialty pharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.04 by $0.03. The specialty pharmaceutical company had revenue of $36.58 million for the quarter, compared to analysts' expectations of $36.27 million. BioDelivery Sciences International had a net margin of 4.23% and a return on equity of 17.84%. View BioDelivery Sciences International's earnings history. What price target have analysts set for BDSI? 9 brokerages have issued 12 month price objectives for BioDelivery Sciences International's stock. Their forecasts range from $7.00 to $9.25. On average, they anticipate BioDelivery Sciences International's stock price to reach $8.46 in the next year. This suggests a possible upside of 64.7% from the stock's current price. View analysts' price targets for BioDelivery Sciences International. Has BioDelivery Sciences International been receiving favorable news coverage? Media coverage about BDSI stock has trended somewhat negative recently, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. BioDelivery Sciences International earned a coverage optimism score of -1.3 on InfoTrie's scale. They also gave media stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about BioDelivery Sciences International. Are investors shorting BioDelivery Sciences International? BioDelivery Sciences International saw a increase in short interest in the month of June. As of June 15th, there was short interest totaling 3,750,000 shares, an increase of 13.3% from the May 31st total of 3,310,000 shares. Based on an average trading volume of 982,300 shares, the days-to-cover ratio is currently 3.8 days. View BioDelivery Sciences International's Short Interest. Who are some of BioDelivery Sciences International's key competitors? Some companies that are related to BioDelivery Sciences International include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT). View all competitors. What other stocks do shareholders of BioDelivery Sciences International own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioDelivery Sciences International investors own include TG Therapeutics (TGTX), NVIDIA (NVDA), Eldorado Gold (EGO), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Baidu (BIDU), Alibaba Group (BABA), Crispr Therapeutics (CRSP), JD.Com (JD) and Square (SQ). Who are BioDelivery Sciences International's key executives? BioDelivery Sciences International's management team includes the following people: Mr. Herm Cukier, CEO & Director (Age 54, Pay $599.46k)Mr. Scott M. Plesha, Pres & Chief Commercial Officer (Age 55, Pay $410.71k)Ms. Mary Theresa Coelho, CFO & Treasurer (Age 58, Pay $410.7k)Mr. James Vollins J.D., Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 51, Pay $340.28k)Dr. Thomas B. Smith FAAFP, M.D., Chief Medical Officer (Age 59, Pay $377.89k) What is BioDelivery Sciences International's stock symbol? BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI." Who are BioDelivery Sciences International's major shareholders? BioDelivery Sciences International's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.65%), Emerald Advisers LLC (2.10%), Emerald Mutual Fund Advisers Trust (1.97%), Wasatch Advisors Inc. (1.44%), Goldman Sachs Group Inc. (1.02%) and Silvercrest Asset Management Group LLC (0.97%). Company insiders that own BioDelivery Sciences International stock include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, James Vollins, Mark A Sirgo, Mary Theresa Coelho, Paolantonio Ernest Robert De, Scott M Plesha and Thomas B Smith. View institutional ownership trends for BioDelivery Sciences International. Which institutional investors are selling BioDelivery Sciences International stock? BDSI stock was sold by a variety of institutional investors in the last quarter, including Aigen Investment Management LP, ClariVest Asset Management LLC, Navellier & Associates Inc, UBS Group AG, Prudential Financial Inc., Silvercrest Asset Management Group LLC, Searle & CO., and 1492 Capital Management LLC. Company insiders that have sold BioDelivery Sciences International company stock in the last year include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, James Vollins, Mark A Sirgo, Mary Theresa Coelho, Scott M Plesha, and Thomas B Smith. View insider buying and selling activity for BioDelivery Sciences International. Which institutional investors are buying BioDelivery Sciences International stock? BDSI stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Marshall Wace LLP, Assenagon Asset Management S.A., Russell Investments Group Ltd., Wasatch Advisors Inc., Globeflex Capital L P, MCF Advisors LLC, and WINTON GROUP Ltd. View insider buying and selling activity for BioDelivery Sciences International. How do I buy shares of BioDelivery Sciences International? Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is BioDelivery Sciences International's stock price today? One share of BDSI stock can currently be purchased for approximately $5.14. How big of a company is BioDelivery Sciences International? BioDelivery Sciences International has a market capitalization of $518.80 million and generates $111.39 million in revenue each year. The specialty pharmaceutical company earns $-15,310,000.00 in net income (profit) each year or $0.10 on an earnings per share basis. BioDelivery Sciences International employs 178 workers across the globe. What is BioDelivery Sciences International's official website? The official website for BioDelivery Sciences International is www.bdsi.com. How can I contact BioDelivery Sciences International? BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at 919-582-9050 or via email at [email protected] This page was last updated on 8/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
